9月22日早盘，体外诊断板块表现活跃，截至上午10：00，其整体上涨3.13%，位居大智慧板块涨幅榜 前列，博晖创新涨停，利德曼也大涨11.76%，硕世生物、达安基因也分别大涨9.17%、9.01%，东方生 物(8.78%)、圣湘生物(8.04%)、明德生物(6.77%)、华大基因(6.39%)、理邦仪器(5.99%)和万泰生物 (6.21%)等个股涨幅也均逾6%。 分析人士表示，体外诊断产业链主要应用场景在医院检验科、独立医学实验室(ICL， IndependentClinicalLaboratory)、体检中心、防疫站、血站等。下游需求端景气度较高，IVD高速增长接 近20%。从终端用户来看，2018年国内IVD产品主要客户公立医院的检查收入达3157亿元、同比增速为 12.48%，重要客户ICL和体检中心行业增速也在20%左右或以上。下游需求旺盛带动上游市场规模的快 速增长，2018年中国IVD行业规模713亿元，同比增长25.6%，远超全球IVD市场6.0%的增速。体外诊断 板块孕育大企业，发光细分景气度佳，具有业绩支撑的龙头股值得关注。(任世碧) ...

来源：广东省药品监督管理局 tto 63 11 简体 | 繁体 开启无障碍 | 开启长者助手 首页 新闻动态 政务公开 政务服务 公众参与 科普曾传 清绮入 您 当前位置：首页 > 政务公开 > 许可信息公开 > 医疗器械 > 医疗器械质量管理体系规范考核 2025年11月医疗器械注册质量管理体系 发布时间：2025-12-24 09:29:59 | 受理号 | 企业名称 | 产品名称 | 生产地址 | 核查 | 结论日期 | | --- | --- | --- | --- | --- | --- | | | | | | 结论 | | | 广东威诺敦生 | | | | 整改 后通 | | | CQZ2501532 | 物医药科技有 限公司 | 医用臭氧治疗仪 | 佛山市顺德区乐从镇水藤村委会创富六路1号联东科创园8座101、201、301 | 过核 | 2025/11/3 | | | | | | 査 | | | 广东百生医疗 | | | | 整改 后通 | | | CQX2501755 器械股份有限 高频手术设备 | 公司 | | 江门市新会区福盛路11号 | 过核 | 2025/11/3 | | | | | ...

12月18日，理邦仪器盘中上涨2.07%，截至09:57，报12.80元/股，成交2231.03万元，换手率0.52%，总 市值74.20亿元。 机构持仓方面，截止2025年9月30日，理邦仪器十大流通股东中，香港中央结算有限公司位居第一大流 通股东，持股3386.87万股，相比上期减少309.93万股。医疗器械ETF（159883）位居第九大流通股东， 持股178.76万股，为新进股东。博道远航混合A（007126）位居第十大流通股东，持股167.37万股，为 新进股东。招商量化精选股票发起式A（001917）退出十大流通股东之列。 责任编辑：小浪快报 理邦仪器所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、养老产业、 多胎概念、体外诊断、智慧医疗等。 截至11月28日，理邦仪器股东户数2.30万，较上期减少2.76%；人均流通股14710股，较上期增加 2.83%。2025年1月-9月，理邦仪器实现营业收入14.46亿元，同比增长4.63%；归母净利润2.57亿元，同 比增长49.29%。 分红方面，理邦仪器A股上市后累计派现11.28亿元。近三年，累计派现3.60亿元。 资金流 ...

Core Insights - The global life support medical device market is projected to reach $75.1 billion in 2024 and is expected to exceed $80 billion in 2025, with a potential to surpass $100 billion in the next five years [3][5] - The domestic life support medical device market in China is rapidly growing, with an estimated market size of 55.7 billion yuan in 2024, expected to reach 61.95 billion yuan in 2025, and potentially reaching 93.2 billion yuan in the next five years [5] Industry Definition and Classification - Life support medical devices are critical equipment used to replace or assist the function of vital organs in emergency situations, primarily utilized in ICUs, emergency rooms, operating rooms, and pre-hospital care [2][3] - Key categories of life support medical devices include blood purification equipment, monitors, ventilators, anesthesia machines, ECG machines, defibrillators, and CPR devices [2][3] Current Industry Development - The life support medical device sector is characterized by high-risk equipment that plays a crucial role in medical rescue and care [3] - The industry has seen rapid market expansion, with significant growth expected in the coming years [3][5] Industry Chain - The upstream of the life support medical device industry includes raw materials, electronic components, biological materials, high-performance batteries, precision sensors, packaging materials, and software systems [5] - The midstream focuses on the research and manufacturing of life support medical devices, while the downstream includes medical institutions, home users, and rehabilitation centers [5] Competitive Landscape - The life support medical device market is marked by high technical barriers and growth potential, with leading domestic companies including Mindray, Yuyue Medical, and Weigao [7] - The market is relatively concentrated, with foreign companies dominating the high-end segment while domestic brands are making breakthroughs in the mid-to-low end and advancing towards high-end products [7] Development Trends - The life support medical device industry is increasingly recognized as essential in modern medicine, with a focus on integrated, precise, and intelligent technologies [10] - The demand for life support medical devices is expected to grow due to the aging population and the rising need for critical care related to severe and emergency patients [10]

Core Viewpoint - The blood gas analyzer market in China is experiencing a transition from large hospitals to grassroots medical institutions, with a significant increase in procurement in 2023, followed by a decline in 2024 and 2025 due to various factors including medical insurance cost control [1][5][9]. Overview - Blood gas analyzers are high-tech diagnostic instruments used to measure parameters such as pH, PCO2, and PO2 in arterial blood, featuring automated calibration and diagnostics [2][3]. - The market for blood gas analyzers is entering a deep adjustment period, with procurement volumes and values showing significant fluctuations [1][9]. Market Policy - The Chinese government emphasizes the development of the medical device industry, including blood gas analyzers, through various policies aimed at ensuring product quality and patient safety [6][7]. Industry Chain - The upstream of the blood gas analyzer industry includes suppliers of raw materials and core components, while the midstream involves R&D and manufacturing, and the downstream consists of hospitals and healthcare institutions as the primary demand market [7][8]. Current Development - In 2023, the total procurement of blood gas analyzers in China reached 965 units, a year-on-year increase of 22.77%, with a total procurement value of 0.95 billion yuan, up 9.20% [1][9]. - The market is seeing a shift in demand from high-end hospitals to grassroots healthcare facilities, with a notable decline in procurement expected in 2024 and 2025 [1][9]. Competitive Landscape - The market has historically been dominated by foreign brands like Radiometer and Wofun, but domestic companies such as Libang and Kangli are gaining market share, with Libang achieving a market share of 24.28% in 2025 [10][12]. - The overall market share of domestic blood gas analyzers reached 48.44% in 2025, indicating a significant shift towards local production and innovation [10][12]. Future Development Trends - The integration of AI algorithms with blood gas analyzers is expected to enhance diagnostic accuracy and provide preliminary treatment suggestions, while advancements in 5G and IoT will facilitate remote data access and device management [14]. - The trend towards miniaturization and ease of use in portable blood gas analyzers is anticipated to grow, catering to various clinical scenarios [14].

| 变更事项 | 变更前 | 变更后 | | --- | --- | --- | | 董事信息 | 张浩、祖幼冬、谢锡城、袁世新、 郑全录、吴瑛、何晴 | 张浩、祖幼冬、谢锡城（职工董事）、 袁世新、郑全录、吴瑛、何晴 | | 监事信息 | 周纯、周奕荣、汪洪潮 | — | 除上述变更事项外，公司营业执照记载的其他事项未发生变化。 特此公告。 深圳市理邦精密仪器股份有限公司 证券代码：300206 证券简称：理邦仪器 公告编号：2025-042 深圳市理邦精密仪器股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市理邦精密仪器股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第六届董事会 2025 年第三次会议，并于 2025 年 11 月 13 日召开 2025 年第一次临时股东会，审议通过了《关于修订<公司章程>》的议案。同时，经 公司第九届职工代表第一次会议与会职工代表投票表决，一致同意选举谢锡城先 生担任公司第六届董事会职工代表董事。以上具体内容可详见公司分别于 2025 年 10 月 ...

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4494.42 points, up 0.15%, with a trading volume of 7.52 billion yuan and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Medical Pulse leading the gainers at 3.65% and Health Road leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, latest price 196.30 yuan, market cap 238 billion yuan, up 1.50%) [1] - Yier Eye Hospital (11.62% weight, latest price 11.40 yuan, market cap 106.31 billion yuan, down 0.26%) [1] - Lejin Medical (4.85% weight, latest price 15.87 yuan, market cap 29.26 billion yuan, up 0.13%) [1] - Aimeike (4.80% weight, latest price 146.26 yuan, market cap 44.26 billion yuan, up 0.83%) [1] - Yuyue Medical (4.66% weight, latest price 35.70 yuan, market cap 35.79 billion yuan, down 0.67%) [1] - Yingke Medical (3.64% weight, latest price 41.53 yuan, market cap 27.21 billion yuan, up 1.94%) [1] - Furuide (3.59% weight, latest price 67.08 yuan, market cap 17.78 billion yuan, up 1.36%) [1] - Meinian Health (3.58% weight, latest price 5.28 yuan, market cap 20.67 billion yuan, down 1.68%) [1] - Sinopharm (3.35% weight, latest price 18.42 yuan, market cap 57.48 billion yuan, down 0.69%) [1] - Ping An Good Doctor (2.63% weight, latest price 13.66 yuan, market cap 29.52 billion yuan, down 1.83%) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 58.83 million yuan, while retail investors saw a net inflow of 78.07 million yuan [1] - Specific stock capital flows include: - Aimeike: Main fund net inflow of 46.99 million yuan, retail net outflow of 30.07 million yuan [2] - Mindray Medical: Main fund net inflow of 33.08 million yuan, retail net outflow of 17.11 million yuan [2] - Furuide: Main fund net inflow of 13.68 million yuan, retail net outflow of 19.08 million yuan [2] Recent Adjustments - The Shenzhen-Hong Kong Medical Index has undergone adjustments in the last 10 days, with one new stock added [2]

Core Viewpoint - The stock of Lifesense Instruments has shown a positive trend, with a year-to-date increase of 27.68% and a market capitalization of 8.121 billion yuan as of November 27 [1]. Financial Performance - For the period from January to September 2025, Lifesense Instruments reported a revenue of 1.446 billion yuan, representing a year-on-year growth of 4.63%. The net profit attributable to shareholders was 257 million yuan, marking a significant increase of 49.29% compared to the previous year [2]. Shareholder Information - As of November 10, 2025, the number of shareholders for Lifesense Instruments was 23,500, a decrease of 3.61% from the previous period. The average number of tradable shares per person increased by 3.74% to 14,407 shares [2]. - The company has distributed a total of 1.128 billion yuan in dividends since its A-share listing, with 360 million yuan distributed over the past three years [3]. Stock Market Activity - On November 27, 2025, Lifesense Instruments experienced a stock price increase of 2.04%, reaching 14.01 yuan per share, with a trading volume of 75.793 million yuan and a turnover rate of 1.63% [1]. - The net inflow of main funds was 5.928 million yuan, with significant buying activity from large orders [1]. Business Overview - Lifesense Instruments, established on August 2, 1995, and listed on April 21, 2011, specializes in the research, production, sales, and service of medical electronic devices and in vitro diagnostic products. The main revenue sources include patient monitoring (29.38%), in vitro diagnostics (20.94%), ultrasound imaging (16.26%), maternal and child health (15.36%), and electrocardiogram diagnostics (15.25%) [1].

Core Insights - The company, RIBON Instruments, reported that as of November 10, 2025, the number of shareholders is 23,486 [2] Company Summary - RIBON Instruments has engaged with investors through an interactive platform, providing updates on shareholder numbers [2] - The company is actively communicating with its investors, indicating a focus on transparency and shareholder engagement [2]

Core Viewpoint - The company, RIBON Instrument (300206), announced the election of Mr. Xie Xicheng as the employee representative director of the sixth board of directors during the first meeting of the ninth employee representative assembly [1] Group 1 - The ninth employee representative assembly was recently held [1] - The employee representatives unanimously agreed to elect Mr. Xie Xicheng [1]